Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.       Anmelden     oder      Jetzt abonnieren!

Archiv: Marktpuls

Reminder: Invitation to Roche’s 3rd Quarter Sales 2025 Presentation » Report
Indirect Property Market Weekly - J. Safra Sarasin - 20. Oktober 2025 » Report
SCHWEIZER INDIKATIONEN: Der SMI notiert vorbörslich freundlich. Feste Amrize, Richemont, freundliche UBS, Novartis, schwächere Roche, Aryzta und feste Technologien die Fakten. Die übrigen Titel werden besser gestellt. Quelle cash Insider
Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment » Report
Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment » Report
FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis » Report
ARYZTA AG: Q3 organic growth on track; Strengthening and accelerating cost optimisations » Report
Holcim Group Services Ltd: Holcim to acquire Xella » Report
Holcim Group Services Ltd: Holcim übernimmt Xella » Report
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer » Report
Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer » Report
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer » Report
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss » Report
Roche: Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss » Report
schönes Wochenende, have a great weekend!
SMG Swiss Marketplace Group Holding AG: SMG announces partial exercise of over-allotment option » Report
GUTEN ABEND: DAILY SMI -0,45% 12'644 SMI Top NESN +2% LONN +1% SCMN GIVN +0,9% KNIN +0,7% NOVN -0,1% Flop PGHN -3,6% UBSG -3,2% AMRZ -2,2% HOLN SREN -2% SREN -1,3% +++ VSMI +6,80% 14.59 +++ DAX -1,82% 23'830 +++ Strasse stabil bis nachgebend +++ (ohne Gewähr) +++ schönes Wochenende, have a great weekend!
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population » Report
Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML » Report
CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis » Report